Drugs / Boya IVIG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06150833 | Sep 2026 → Sep 2028 expected | immunodeficiency disease | Azidus Brasil | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Boya IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06150833 ↗ |
| Modality | Protein / enzyme biologic | “5% human immunoglobulin” NCT06150833 ↗ |
| Route | Intravenous | “for intravenous administration” NCT06150833 ↗ |